The estimated Net Worth of Kelly Culwell is at least $2.13 millió dollars as of 30 April 2020. Kelly Culwell owns over 2,000 units of Evofem Biosciences Inc stock worth over $1,748 and over the last 7 years he sold EVFM stock worth over $23,770. In addition, he makes $2,101,180 as Chief Medical Officer at Evofem Biosciences Inc.
Kelly has made over 4 trades of the Evofem Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of EVFM stock worth $9,420 on 30 April 2020.
The largest trade he's ever made was buying 3,000 units of Evofem Biosciences Inc stock on 16 August 2018 worth over $6,720. On average, Kelly trades about 333 units every 30 days since 2018. As of 30 April 2020 he still owns at least 194,226 units of Evofem Biosciences Inc stock.
You can see the complete history of Kelly Culwell stock trades at the bottom of the page.
Dr. Kelly Culwell M.D. serves as Chief Medical Officer of the Company. Dr. Culwell has also served as the Chief Medical Officer of WCG Cares since November 2017, and also became a director of the board of WCG Cares in January 2019 with a term of 3 years until December 31, 2021. Prior to joining WCG Cares, Dr. Culwell was the Medical Director of Planned Parenthood of the Pacific Southwest and maintained an academic clinical practice as the Director of Family Planning and Associate Clinical Professor at University of California, Davis. Dr. Culwell previously served as a Medical Officer with the World Health Organization where she developed global guidelines for clinical practice and is widely published in peer reviewed journals. Dr. Culwell received a Bachelor of Science from California Lutheran University, a Medical Doctorate from the University of California, Davis and a Masters of Public Health from Northwestern University. Dr. Culwell completed her post-graduate training in Obstetrics and Gynecology at University of California San Diego and her Family Planning Fellowship at Northwestern University. Dr. Culwell maintains appointments as Volunteer Assistant Clinical Professor in the Departments of Obstetrics and Gynecology at the University of California, Davis and San Diego campuses. Dr. Culwell is qualified as a Diplomat from the American Board of Obstetrics and Gynecology.
As the Chief Medical Officer of Evofem Biosciences Inc, the total compensation of Kelly Culwell at Evofem Biosciences Inc is $2,101,180. There are 1 executives at Evofem Biosciences Inc getting paid more, with Saundra Pelletier having the highest compensation of $2,803,980.
Kelly's mailing address filed with the SEC is C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130.
Over the last 7 years, insiders at Evofem Biosciences Inc have traded over $32,368,585 worth of Evofem Biosciences Inc stock and bought 12,978,479 units worth $54,857,186 . The most active insiders traders include Research Corp Acacia, Fund Solutions Ltd Link és Biopharma, Inc. Pdl. On average, Evofem Biosciences Inc executives and independent directors trade stock every 38 days with the average trade being worth of $5,281. The most recent stock trade was executed by Yan Zhang on 12 January 2024, trading 104 units of EVFM stock currently worth $4.
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.
Evofem Biosciences Inc executives and other stock owners filed with the SEC include: